Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Anrikefon (HSK21542) in Healthy Volunteers
NCT04110886Phase 1Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in postoperative pain and chronic pain comparing HSK21542 SAD with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events and Number of subjects with abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters. Started Jul 2020; status: completed.
02
Drugs
hsk21542
03
Conditions
postoperative painchronic pain
Beyond the preview
Go deeper on NCT04110886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110886.